Publications by authors named "O Caffo"
Introduction: Over the years, several prognostic models were developed in patients receiving chemotherapy for metastatic castration resistant prostate cancer (mCRPC), while data on androgen-receptor signaling inhibitors (ARSI) in a real-world setting are limited.
Patients And Methods: We compared a consecutive series of 565 mCRPC patients receiving first-line ARSI at 4 high-volume Italian Centers (development set) to an external series of 180 patients receiving the same treatment at another Italian high-volume Center (training set), between 2011 and 2022. Sixteen clinical and baseline laboratory variables were selected to develop a prognostic model.
Article Synopsis
- About 20% of prostate cancer patients have alterations in HRR genes like BRCA1/2, which are important biomarkers for treatment with PARP inhibitors like Olaparib, currently approved for metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations in Italy.
- A survey of 108 oncologists revealed that only 52.8% regularly test all metastatic prostate cancer patients for BRCA mutations, and many face challenges such as long wait times and unclear procedures.
- These obstacles hinder the effective implementation of genetic testing, limiting access to personalized PARP inhibitor treatment and highlighting the need for improved molecular testing processes in clinical settings.
Background: In recent years, theranostics has become a promising approach for treating metastatic castration-resistant prostate cancer (mCRPC), with trials investigating targeted radioligand therapy, particularly using prostate-specific membrane antigen labeled with lutetium-177 ([Lu]Lu-PSMA). The proper position of [Lu]Lu-PSMA in the therapeutic algorithm of mCRPC is yet to be identified.
Design, Setting, And Participants: We conducted a systematic review and meta-analysis of phase II/III randomized controlled trials to assess the efficacy of [Lu]Lu-PSMA in treating mCRPC.
Background And Objective: Apalutamide (APA) is a treatment for metastatic castration-sensitive prostate cancer (mCSPC). In the ARON-3 study we investigated real-world experiences with APA treatment for mCSPC.
Methods: We retrospectively assessed real-world clinical outcomes for patients with mCSPC treated with APA in the ARON-3 study.
Article Synopsis
- The IMDC score is crucial for predicting outcomes and guiding treatment in patients with metastatic renal cell carcinoma (mRCC), especially when starting therapy with nivolumab.
- A multicenter study analyzed 492 mRCC patients to see how changes in IMDC categories affected their overall survival (OS) and progression-free survival (PFS) after starting nivolumab.
- Results indicated that patients maintaining or improving their IMDC category had better survival outcomes compared to those whose condition worsened, highlighting the importance of IMDC monitoring in mRCC treatment.